With Prevnar Challenger Fully Funded, Affinivax Raises $120m For Other Novel Vaccines
Executive Summary
Astellas is funding the company’s Phase II vaccine against 24 pneumococcal serotypes. Affinivax will use its series B venture cash to advance its MAPS vaccines for bacterial and viral infections and cancer.
You may also be interested in...
Pfizer’s 20-Valent Vaccine And Prevnar Successor Succeeds In Phase III
The company still plans to file 20vPnC for US FDA approval by the end of 2020 after the pneumococcal vaccine was non-inferior to Prevnar and to Pneumovax on six additional serotypes in older patients.
Astellas Builds Vaccine Portfolio With Affinivax Pneumococcal Candidate
Despite one recent setback, Astellas is continuing to expand its vaccines business through a new global deal for Affinivax's lead MAPS pneumococcal product, in a move that builds on earlier research links between the companies.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.